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Is 5% Imiquimod cream more efficacious at sustained clearance of
genital warts at 3 months compared to 1% Imiquimod, ablation
therapy, and a placebo vehicle cream?
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Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

June 15, 2011

ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine whether or not 5%
Imiquimod is more efficacious at sustained treatment of genital warts at 3 months compared to
1% Imiquimod, ablation, and a placebo vehicle cream.
STUDY DESIGN: Primary literature published between 1996 and the present.
DATA SOURCES: RCT’s were found using Ovid, PubMed, Medline, and Cochrane databases.
OUTCOMES MEASURED: The outcomes measured were a sustained clearance of genital warts
at 3 months. The outcomes were measured by photographs, measurements, counts, locations, and
mapping.
RESULTS: Three RCTs were included in this review. RCTs conducted by Beutner and Edwards
(separate articles) showed that Imiquimod 5% is superior to most methods including different
ablation therapies and Imiquimod 1%. One RCT by Schofer showed possibly Imiquimod used in
combination with ablation may be superior to other treatments.
CONCLUSION: All three RCTs showed that Imiquimod 5% is more effective in clearing genital
warts and sustaining clearance at 3 months as compared to Imiquimod 1%, ablation, and placebo.
KEYWORDS: Genital warts, HPV, Imiquimod, ablation, and placebo.
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INTRODUCTION
Genital warts caused by HPV are one of the most common STDs in the world and
encountered by the medical practitioner. Currently there are many different treatments for genital
warts including lotions, creams, cryosurgery, ablation, and excision.
An estimated 30-50% of sexually active adults are infected with HPV. It is estimated that
up to 1% actually have genital warts caused by strains 16 and 21. Genital warts that do appear
will either progress or regress, although this process is not completely understood. Standard
treatment regimens of excision, ablation, and cryosurgery are only directed at the lesion instead
of the cause.
Regression on genital wart and HPV is thought to be due to an immune response, but is
still widely unknown. Sustained clearance is still relatively random from patient to patient,
however, it is thought to be improved with immune-response modifiers (Imiquimod).
There are no approved OTC therapies for the treatment of genital warts caused by HPV.
Prescription drugs include Imiquimod (Aldara), Podophyllotoxin (Podofilox). Other methods
include ablation, cryotherapy, excision, and podophyllin resin.
These prescription drugs are many times successful for the eradication of initial genital
warts, however, sustained clearance is still difficult to predict.
OBJECTIVE
The objective of this systematic review is to determine whether or not 5% Imiquimod is
more efficacious at sustained treatment of genital warts at 3 months compared to 1% Imiquimod,
ablation, and a placebo vehicle cream.
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METHODS
Criteria for the selection of studies included healthy men and women 18 years old and
older. The intervention used was 5% Imiquimod cream with comparisons against 1% Imiquimod
cream, ablation therapy, and placebo vehicle cream. The outcomes measured were the recurrence
of genital warts after treatment with the above therapies at 3 months post-treatment. The method
was to find RCTs with similar inclusion and exclusion criteria. For example all the three RCTs
used for this systematic review required healthy man and women at least 18 years of age, and
excluded patients who were imunnosupressed or recently treated for genital warts using the
treatments in question. It is of note that each study had additional inclusion and exclusion
criteria.
The types of studies used were RCTs comparing 5% Imiquimod to 1% Imiquimod and
placebo, 5% Imiquimod and 1% Imiquimod to placebo, and 5% Imiquimod to ablation alone and
combined.
The key words used in this review include genital warts, HPV, Imiquimod, ablation, and
placebo. All articles were published in English and peer-reviewed. Searches were conducted
David A Smith using PubMed, Ovid, and Medline. All articles were selected by Patient Oriented
Evidence that Matters (POEM). All articles had to rely on primary literature published between
1996 to present, with at least 2 RCTs. All articles had to contain POEMs. Summary of statistics
reported or used were p-values; RRR; ARR; and NNT.
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Table 1 - Demographics & Characteristics of Included Studies
Study
Type

#
Patients
279

Age
(yrs)
18+

Beutner,
USA,
1998

RCT;
doubleblind;
parallelgroup
study

Edwards,
USA,
1998

RCT;
doubleblind;
placebo
controlled

311

18+

Schofer,
RCT; 3Germany,
arm
2006
comparison

377

18+

Inclusion
Criteria

Exclusion
Criteria

Healthy
HIV (+);
men &
Pregnant (+);
women, Tx within 4 weeks of
>= 2 to
study;
<= 50
Pre-study pap smear
warts at
= HSIL
least
10mm in
area
Healthy
Immunosuppressed;
men &
HSIL;
women, Pregnant or lactating;
>= 2 to
Drug/etoh
<= 50
dependency; other
warts at
skin disease; Rx in
least
the area within 2
50mm in
weeks; wart Tx
area
within 4 weeks
Healthy
Previous use of 5%
men &
Imiquimod within 6
women
months; any Tx with
with
interferon,
external
immunomodulators,
genital
oral antivirals;
warts up
cytotoxic drugs;
to
pregnant or lactating
2000mm
women;
area and immunocompromised
up to 1
inch

W/D Interventions

72

5%
Imiquimod;
1%
Imiquimod;
Placebo

77

5%
Imiquimod;
1%
Imiquimod;
Placebo

91

5%
Imiquimod;
Ablation; 5%
Imiquimod &
Ablation
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OUTCOMES MEASURED
The outcomes measured were a sustained clearance of genital warts at 3 months. The
outcomes were measured by photographs, measurements, counts, locations, and mapping.
RESULTS
The primary efficacy parameter was based upon all individuals who were completely
cleared of all genital warts at 12 or 16 weeks and successfully followed up for 3 months.
Schofer et al reported a sustained clearance of 83.9% for ablation therapy, 93.8% for 5%
Imiquimod, and 91.7% for ablation and 5% Imiquimod. The difference between 5% Imiquimod
treatment is statistically significant with p = 0.074. The ARR was calculated to be -0.099 and the
RRR was -0.615. The NNT was 48.
Beutner et al sustained clearance 81% for 5% Imiquimod, 83% for 1% Imiquimod, and
100% for placebo. The ARR was calculated to be -0.38 and the RR was -0.44. The NNT was -5
Edwards et al reported a sustained clearance of 87% for Imiquimod 5%, 100% for
Imiquimod 1%, and 90% placebo. The ARR was calculated to be 0.3 and the RRR was 0.3. The
NNT was -8.
Table 2 - Efficacy of Imiquimod 5% in Sustained Clearance at 3 Months
Study

Imiquimod
5% (SCP)
Edwards 39/45
et al
(87%)
Beutner 39/48
et al
(81%)
Schofer 94/100
et al
(93.8%)

Imiquimod
1% (SCP)
18/18
(100%)
10/12
(83%)
N/A

Ablation
(SCP)
N/A
N/A

Placebo C.I. RRR
(SCP)
9/10
NR 0.3
(90%)
100%
NR -0.44

ARR

NNT

0.3

-8*

pvalue
NR

-0.38

-5**

NR

77/92
N/A
NR -0.615 -0.099 48***
(83.9%)
&
69/75
(91.7%)*
*NNT compares Imiquimod 5% to Imiquimod
**NNT compares Imiquimod 5% to Placebo
***NNt compares Imiquimod 5% to Ablation & Imiquimod 5% combined treatment

0.074

Smith: Imiquimod & Sustained Clearance 5

SCP = Sustained Clearance Percentage, C.I. = Confidence Interval, RRR = Relative Risk
Reduction, ARR = Absolute Risk Reduction, NNT = Numbers Needed to Treat
*91.7 % was recorded with a combination of Imiquimod 5%.
Although all three studies measured total clearance of genital warts over a period of 12 to
16 weeks, this systematic review was concerned with the sustained clearance of at least 3 months
of initial genital warts that were measured and removed by the above treatments. All three
studies reported that 5% Imiquimod had the highest percentage of initial clearance; however,
sustained clearance did not produce the same results.
In the studies conducted by Edwards and Beutner 1% Imiquimod and placebo both
reported a higher percentage of sustained clearance. Schofer reported 5% Imiquimod with the
highest percentage of sustained clearance.
Table 3 – Reported Adverse Reaction of Moderate Erythema at Application Site
Study

5% Imiquimod

1% Imiquimod

Vehicle or Ablation

Beutner et al

40 (43.5%)

N/A

8 (8.7%) Vehicle

Edwards et al

36/106 (34%)

4/106 (4.1%)

3/106 (3.2%) Vehicle

Schofer et al

56.7%
N/A
N/A Ablation
55% with ablation
*Beutner and Edwards reported at 16 weeks (total treatment phase); Schofer reported at 4
weeks.
The most common side effect and complaint in all three studies was moderate erythema
at the application site. It was reported that 40%, 56.7%, and 34% of the 5% Imiquimod group in
the Beutner et al, Schofer et al, and Edwards et al studies respectively experienced these
symptoms. The 1% Imiquimod group reported moderate erythema in only 4.1% in the Edwards
et al study.
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In all three studies patients were instructed on how to apply 1% Imiquimod, 5%
Imiquimod, and place vehicle cream. Patients receiving cryotherapy/ablation were treated on an
outpatient basis. No study had direct supervision of application, other than assessing wart
clearance at different time intervals. Edwards et al saw patients weekly for the first 2 weeks and
then biweekly for 16 weeks. Patients who had complete clearance were entered into a 12 week
follow-up phase. Schofer et al conducted an initial 16 week treatment phase with a 1 month, 3
month, and 6 month follow-up for those who initially cleared during the treatment phase. In the
Beutner et al study patients were evaluated weekly for the first 4 weeks and every 2 weeks for
the 16 week treatment phase. A 12 week follow-up was performed for those patients who had
initial clearance during the treatment phase.
DISCUSSION
Topical Imiquimod is an immune response modifier that has been shown to exhibit
antitumor and antiviral properties. It is an imidazoquinolin heterocyclic amine that can increase
interferon alpha production. Interferon alpha is still very expensive and has been shown to
effectively treat anogenital warts.
Each study had a different modality that proved to be more effective on a percentage
basis for sustained clearance at 3 months. In the Edwards et al study 5% Imiquimod had a higher
recurrence rate than that of 1% Imiquimod and placebo cream, however, that may be due to the
fact that total 5% Imiquimod had more patients in the follow-up phase with 45; while 1%
Imiquimod had only 18 patients and place cream with 10.
The Beutner et al reported that placebo cream had the highest sustained clearance at 3
months but did not report how many patients were involved in the follow-up phase. In the same
study 1% Imiquimod reported a higher percentage (83%) than 5% Imiquimod (81%) but again
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the 5% Imiquimod group had more patients at 48 compared to 12 patients with the 1%
Imiquimod group.
Finally, the Schofer et al study reported 5% Imiquimod with highest sustained clearance
compared to ablation and 5% Imiquimod combined with ablation. In this study 5% Imiquimod
had the highest total of follow-up patients with 100.
All three studies were utilized for this systematic review without any significant
limitations to the studies themselves.
CONCLUSION
The studies reviewed demonstrated that 5% Imiquimod therapy alone is not the most
effective treatment at sustaining genital wart clearance at 3 months when initially cleared with
the same therapy. Each study produced a different answer to the proposed hypothesis. At this
time there is not enough data to support that any one therapy is superior to another in sustaining
clearance at 3 months. Although 5% Imiquimod is superior in establishing an initial baseline
clearance of genital warts, an individual’s immune response may play a more vital role in
sustainment of clearance than supporting initial clearance. This is impossible to assess since the
studies do not report the age of participants, only that they have to be at least 18 years old.
Ideally the best systematic review would have an equal number of patients in the followup phase with similar ages regardless of therapeutic intervention; however, this may not be
possible to due to the fact that some treatments are more efficacious than others at establishing
initial clearance, which mean inevitably the number of patients in follow-up will be skewed.

References
1. Beutner KR, Tyring SK, Trofatter KF, Douglas JM, Spruane S, Owens ML, Fox T,
Hougham A, Schmitt KA. Imiquimod, a Patient-Applied Immune-Response Modifier for
Treatment of External Genital Warts. Antimicrobial Agents And Chemotherapy. 1998;
42(4):789-794.
2. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox L, Hougham AJ, Schmitt KA.
Self Administered Topical 5% Imiquimod Cream for External Anogenital Warts. Arch
Dermatol. 1998; 134:25-30.

3. Schofer H, Ophoven AV, Henke U, Lenz T, Eul A. Randomized, comparative trial on the
sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods
in external anogenital warts. European Journal of Dermatology. 2006; 16(6):642-648.
4. Chorba T, Tau G, Irwin K. "National Institute of Health." U.S. Department of Health and
Human Services . NIH, 2007. Web. 15 Jun 2011. <http://www.nih.gov/>.

